Pharmacokinetics of CAR T cells in multiple myeloma 1 the good, the bad, and the ugly
CAR T cells directed against B-cell maturation antigen (BCMA) have now evolved into an established standard of care for patients with relapsed or refractory multiple myeloma (RRMM).
Evidence level: Számítógépes vagy elméleti. Modellből vagy adatbányászatból származó jel.
Related signals
- Apalutamide Treatment and Metastasis‑free Survival in Prostate Cancer
- The prostate cancer conundrum revisited: Treatment changes and prostate cancer mortality declines
- The contemporary management of prostate cancer
- Extracellular TROP2 Fragment Identified as a Potential Biomarker and Metastasis Driver
- Overall survival of prostate cancer patients treated with Lu‑177 PSMA 617 (Pluvicto®) in a multidisciplinary setting— a single center experience